PureTech Health plc (PRTC)
NASDAQ: PRTC · Real-Time Price · USD
14.79
+0.09 (0.61%)
Sep 17, 2025, 4:00 PM EDT - Market closed
PureTech Health Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for PureTech Health.
Price Target: $ (0.00%)
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for PureTech Health.
Recommendation Trends
Rating | Apr '24 | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 |
---|---|---|---|---|---|---|
Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Buy | 2 | 2 | 2 | 2 | 2 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 2 | 2 | 2 | 2 | 2 | 0 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Leerink Partners | Leerink Partners | Buy Initiates $45 | Buy | Initiates | $45 | +204.26% | Sep 9, 2024 |
Piper Sandler | Piper Sandler | Buy Maintains $37 → $44 | Buy | Maintains | $37 → $44 | +197.50% | Aug 25, 2022 |
SVB Leerink | SVB Leerink | Buy Maintains $66 → $70 | Buy | Maintains | $66 → $70 | +373.29% | Aug 9, 2022 |
SVB Leerink | SVB Leerink | Buy Maintains $70 → $66 | Buy | Maintains | $70 → $66 | +346.25% | Jun 15, 2022 |
SVB Leerink | SVB Leerink | Buy Maintains $76 → $70 | Buy | Maintains | $76 → $70 | +373.29% | Jan 7, 2022 |
Financial Forecast
Revenue This Year
n/a
from 4.83M
Revenue Next Year
n/a
EPS This Year
-0.61
from 0.21
EPS Next Year
-0.66
from -0.61
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 |
---|---|---|---|
High | n/a | n/a | |
Avg | n/a | n/a | |
Low | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 |
---|---|---|---|
High | - | - | |
Avg | - | - | |
Low | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 |
---|---|---|---|
High | -0.63 | -0.68 | |
Avg | -0.61 | -0.66 | |
Low | -0.59 | -0.64 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 |
---|---|---|---|
High | - | - | |
Avg | - | - | |
Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.